These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 26278069)

  • 21. T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide.
    James EA; Kwok WW; Ettinger RA; Thompson AR; Pratt KP
    J Thromb Haemost; 2007 Dec; 5(12):2399-407. PubMed ID: 18034765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epitope specificity and inactivation mechanisms of factor VIII inhibitor antibodies.
    Scandella D
    Vox Sang; 1999; 77 Suppl 1():17-20. PubMed ID: 10529680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site.
    Scandella D; Gilbert GE; Shima M; Nakai H; Eagleson C; Felch M; Prescott R; Rajalakshmi KJ; Hoyer LW; Saenko E
    Blood; 1995 Sep; 86(5):1811-9. PubMed ID: 7544643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic.
    Scandella DH; Nakai H; Felch M; Mondorf W; Scharrer I; Hoyer LW; Saenko EL
    Thromb Res; 2001 Mar; 101(5):377-85. PubMed ID: 11297754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kinetic parameters of monoclonal antibodies ESH2, ESH4, ESH5, and ESH8 on coagulation factor VIII and their influence on factor VIII activity.
    Egler C; Albert T; Brokemper O; Zabe-Kühn M; Mayer G; Oldenburg J; Schwaab R
    J Mol Recognit; 2009; 22(4):301-6. PubMed ID: 19266540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation.
    Meeks SL; Healey JF; Parker ET; Barrow RT; Lollar P
    Blood; 2007 Dec; 110(13):4234-42. PubMed ID: 17848617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene.
    Pashov AD; Calvez T; Gilardin L; Maillère B; Repessé Y; Oldenburg J; Pavlova A; Kaveri SV; Lacroix-Desmazes S
    Haemophilia; 2014 Mar; 20(2):176-84. PubMed ID: 24118514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural basis for inhibition of coagulation factor VIII reveals a shared antigenic hotspot on the C1 domain.
    Childers KC; Cowper B; Vaughan JD; McGill JR; Davulcu O; Lollar P; Doering CB; Coxon CH; Spiegel PC
    J Thromb Haemost; 2024 Sep; 22(9):2449-2459. PubMed ID: 38849084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization.
    Scandella D; Mattingly M; de Graaf S; Fulcher CA
    Blood; 1989 Oct; 74(5):1618-26. PubMed ID: 2477082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement.
    Spena S; Garagiola I; Cannavò A; Mortarino M; Mannucci PM; Rosendaal FR; Peyvandi F;
    J Thromb Haemost; 2018 Apr; 16(4):778-790. PubMed ID: 29399993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The humoral response to human factor VIII in hemophilia A mice.
    Healey JF; Parker ET; Barrow RT; Langley TJ; Church WR; Lollar P
    J Thromb Haemost; 2007 Mar; 5(3):512-9. PubMed ID: 17181826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor.
    Jacquemin M; Benhida A; Peerlinck K; Desqueper B; Vander Elst L; Lavend'homme R; d'Oiron R; Schwaab R; Bakkus M; Thielemans K; Gilles JG; Vermylen J; Saint-Remy JM
    Blood; 2000 Jan; 95(1):156-63. PubMed ID: 10607698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development.
    d'Oiron R; Pipe SW; Jacquemin M
    Haemophilia; 2008 Jul; 14 Suppl 3():138-46. PubMed ID: 18510534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First report of real-time monitoring of coagulation function potential and IgG subtype of anti-FVIII autoantibodies in a child with acquired hemophilia A associated with streptococcal infection and amoxicillin.
    Takeyama M; Nogami K; Kajimoto T; Ogiwara K; Matsumoto T; Shima M
    Int J Hematol; 2018 Jan; 107(1):112-116. PubMed ID: 28597369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays.
    Pavlova A; Delev D; Pezeshkpoor B; Müller J; Oldenburg J
    Thromb Haemost; 2014 May; 111(5):851-61. PubMed ID: 24452774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure of blood coagulation factor VIII in complex with an anti-C1 domain pathogenic antibody inhibitor.
    Gish JS; Jarvis L; Childers KC; Peters SC; Garrels CS; Smith IW; Spencer HT; Doering CB; Lollar P; Spiegel PC
    Blood; 2021 May; 137(21):2981-2986. PubMed ID: 33529335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between the binding sites for von Willebrand factor, phospholipid, and human factor VIII C2 inhibitor alloantibodies within the factor VIII C2 domain.
    Nogami K; Shima M; Giddings JC; Takeyama M; Tanaka I; Yoshioka A
    Int J Hematol; 2007 May; 85(4):317-22. PubMed ID: 17483075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cross-reacting Material-positive Hemophilia A Diagnosed in a Patient with a Spontaneous Thigh Hemorrhage.
    Saito T; Mukae J; Nakamura Y; Inaba H; Nogami K; Koyama T; Fukutake K; Yamamoto K
    Intern Med; 2017; 56(13):1719-1723. PubMed ID: 28674365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.
    Chao BN; Baldwin WH; Healey JF; Parker ET; Shafer-Weaver K; Cox C; Jiang P; Kanellopoulou C; Lollar P; Meeks SL; Lenardo MJ
    J Thromb Haemost; 2016 Feb; 14(2):346-55. PubMed ID: 26588198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of factor VIII inhibitors.
    Shima M
    Int J Hematol; 2006 Feb; 83(2):109-18. PubMed ID: 16513528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.